Tadehaginoside

Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes[1][2].

Product Specifications

CAS Number

[2020004-61-7]

UNSPSC

12352005

Target

Keap1-Nrf2; NF-κB

Related Pathways

NF-κB

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

OC(C=C1)=CC=C1/C=C\C(OC[C@H]([C@H]([C@@H]([C@H]2O)O)O)O[C@H]2OC3=CC(O)=CC(O)=C3)=O

Molecular Formula

C21H22O10

Molecular Weight

434.39

References & Citations

[1]Tang A, et al. Antihepatotoxic effect of tadehaginoside, extracted from Tadehagi triquetrum (L.), against CCl4-lesioned rats through activating the Nrf2 signaling pathway and attenuating the inflammatory response. Inflammation. 2014 Aug;37 (4) :1006-14.|[2]Zhang X, et al. Tadehaginoside modulates lipogenesis and glucose consumption in HepG2 cells. Nat Prod Res. 2015;29 (24) :2287-90.